Advancements in Radiopharmaceutical Theranostics
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 79
Special Issue Editors
Interests: antibody-drug conjugates; radiotheranostics; bioconjugation; targeted radionuclide therapy; nanobody-drug conjugates; antibody-radionuclide conjugates; radiochemistry; biorthogonal click chemistry
Special Issues, Collections and Topics in MDPI journals
Interests: radiotheranostics; radiopharmaceutical synthesis; radiometal chelation; drug discovery; fluorescence spectroscopy; fluorescence image-guided surgery
Interests: radiotheranostics; radiochemistry; targeted radionuclide therapy; molecular imaging; radiometal chelation; bioconjugation; bioorthogonal click chemistry
Special Issue Information
Dear Colleagues,
Theranostics is a rapidly growing field in medical science, demonstrating remarkable advancements over the past decade. Radiopharmaceutical theranostics, the most clinically established application of theranostics, combines molecules possessing specificity for biological features amplified in disease-associated sites with radionuclides of varied emission profiles of medical relevance. By leveraging a targeting vector of biologically inspired design, theranostic radiopharmaceuticals can accurately deliver radioactivity to the disease location, enhancing the imaging quality and therapeutic efficacy while significantly reducing damage to healthy tissues. Furthermore, the modular nature provided by theranostics, through which the vector molecule’s chemical properties as well as the physical nature of the radionuclide’s decay scheme can be optimized based on both the disease’s nature and the patient’s specific needs, is paving the way for more personalized and efficient healthcare.
This Special Issue invites scientists and healthcare professionals to contribute their expert opinion and groundbreaking research findings on radiopharmaceutical theranostics. We welcome original research articles, reviews, and short communications that explore technical advancements in radiopharmaceutical theranostics, including, but not limited to, the use of novel targeting ligands, such as small molecules, peptides, and biologics as well as emerging radionuclides such as alpha particle emitters, including 225Ac and 211At, and the incorporation of true radiotheranostic isotope pairs, such as 64Cu/67Cu. Also of great interest are manuscripts detailing innovative discoveries in radiochemistry and imaging-derived dosimetry measurements. In addition, we welcome discussions regarding the challenges associated with the clinical translation of radiopharmaceutical theranostics.
Dr. Aiko Yamaguchi
Dr. Shilpa Sharma
Dr. Ryan Patrick Coll
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- radiotheranostics
- emerging radionuclides
- radiometals
- image-guided dosimetry
- alpha-emitters
- PET
- SPECT
- radioligand therapy
- targeted radionuclide therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
